Doping in sport in Uzbekistan: problems, causes, and solutions

  • Authors: Azamjon Bahodirovich Soliev, Аbdushukur Аbdujamilevich Sadikov
  • National Anti-Doping Agency of Uzbekistan, Turin Polytechnic University. Tashkent, Uzbekistan
Abstract 

This article examines the growing issue of doping in sport in Uzbekistan within the context of rapid national sports development and increasing international competitiveness. It highlights how state-led reforms, enhanced infrastructure, and strong incentive systems have contributed to significant athletic achievements, while simultaneously intensifying performance pressure on athletes. 

The study identifies doping as a multifaceted problem driven by both systemic and individual factors, including high expectations for success, insufficient antidoping education, inadequate medical supervision, and the influence of coaches or support personnel. Statistical analysis of 2021-2024 data reveals that the majority of violations involve anabolic agents (48.5%), followed by hormone modulators and diuretics, indicating a pattern of misuse of accessible pharmacological substances. The article further explores common athlete errors, such as unsupervised medication use and lack of awareness regarding prohibited substances and Therapeutic Use Exemptions (TUEs). It emphasizes the serious health consequences associated with doping, including cardiovascular, endocrine, and psychological risks, framing doping not only as a regulatory violation but also as a public health concern. 

To address these challenges, the authors propose a comprehensive prevention strategy centered on education, stricter medical oversight, institutional strengthening of anti-doping agencies, and increased accountability for all stakeholders. The study concludes that sustainable sports development in Uzbekistan depends on fostering a culture of clean sport grounded in ethics, awareness, and compliance with international anti-doping standards.

References 

https://www.wada-ama.org/en/2022-annualreport. 

https://www.wada-ama.org/en/2023-annualreport.

 https://www.wada-ama.org/en/2024-annualreport.

 https://www.wada-ama.org/en/resources/worldanti-doping-code-and-internationalstandards/prohibited-list#resourcedownload. 

Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014). Adverse health consequences of performanceenhancing drugs. Endocrine Reviews. 

Nieschlag, E., & Vorona, E. (2015). Medical consequences of doping with anabolic androgenic steroids. European Journal of Endocrinology.

 Kalvinsh, I. (2015). Mildronate: An antiischemic drug for neurological indications. CNS Drug Reviews 

Verbalis, J. G. (2010). Disorders of body water homeostasis. Best Practice & Research Clinical Endocrinology & Metabolism. 

Lippi, G., & Guidi, G. C. (2007). Blood doping by erythropoietin: Scientific and ethical issues. British Journal of Sports Medicine. World Anti-Doping Code, 2021. 

https://zamin.uz/uz/sport/135271-olimpiadachempionlari-va-sovrindorlari-qandaytaqdirlandi.html. 

https://olympic.uz/oz/news/1054. https://kun.uz/66625336. 

International Standard on Therapeutic Use Exemptions (ISTUE), 2023.

View PDF version
Back to articles